Senior Trial Manager
I have been working in trial management since 2005, primarily on later Phase II and Phase III CTIMPs, within an oncology setting. My current research interests are CTIMPs in paediatric populations.
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial
Marcovecchio ML. et al, (2020), Wellcome Open Research, 5, 49 - 49
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
Urbonas V. et al, (2019), Annals of Oncology, 30, 317 - 324
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Iveson TJ. et al, (2018), The Lancet Oncology, 19, 562 - 578
Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma
Middleton MR. et al, (2017), Clinical Trials
Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.
Iveson T. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35